Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1994 1
1995 2
1997 1
2003 1
2006 2
2007 2
2008 2
2011 2
2012 1
2013 3
2014 1
2015 1
2016 1
2017 1
2020 2
2021 1
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Cysteine metabolic engineering and selective disulfide reduction produce superior antibody-drug-conjugates.
Procopio-Melino R, Kotch FW, Prashad AS, Gomes JM, Wang W, Arve B, Dawdy A, Chen L, Sperry J, Hosselet C, He T, Kriz R, Lin L, Marquette K, Tchistiakova L, Somers W, Rouse JC, Zhong X. Procopio-Melino R, et al. Among authors: marquette k. Sci Rep. 2022 May 4;12(1):7262. doi: 10.1038/s41598-022-11344-z. Sci Rep. 2022. PMID: 35508689 Free PMC article.
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.
Hooper AT, Marquette K, Chang CB, Golas J, Jain S, Lam MH, Guffroy M, Leal M, Falahatpisheh H, Mathur D, Chen T, Kelleher K, Khandke K, Muszynska E, Loganzo F, Rosfjord E, Lucas J, Kan Z, Subramanyam C, O'Donnell C, Neri D, Gerber HP, May C, Sapra P. Hooper AT, et al. Among authors: marquette k. Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472. doi: 10.1158/1535-7163.MCT-22-0099. Mol Cancer Ther. 2022. PMID: 35793468 Free PMC article.
Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.
Root AR, Guntas G, Katragadda M, Apgar JR, Narula J, Chang CS, Hanscom S, McKenna M, Wade J, Meade C, Ma W, Guo Y, Liu Y, Duan W, Hendershot C, King AC, Zhang Y, Sousa E, Tam A, Benard S, Yang H, Kelleher K, Jin F, Piche-Nicholas N, Keating SE, Narciandi F, Lawrence-Henderson R, Arai M, Stochaj WR, Svenson K, Mosyak L, Lam K, Francis C, Marquette K, Wroblewska L, Zhu HL, Sheehan AD, LaVallie ER, D'Antona AM, Betts A, King L, Rosfjord E, Cunningham O, Lin L, Sapra P, Tchistiakova L, Mathur D, Bloom L. Root AR, et al. Among authors: marquette k. MAbs. 2021 Jan-Dec;13(1):1850395. doi: 10.1080/19420862.2020.1850395. MAbs. 2021. PMID: 33459147 Free PMC article.
Tyrosine Sulfation at Antibody Light Chain CDR-1 Increases Binding Affinity and Neutralization Potency to Interleukine-4.
D'Antona AM, Lee JM, Zhang M, Friedman C, He T, Mosyak L, Bennett E, Lin L, Silverman M, Cometa F, Meade C, Hageman T, Sousa E, Cohen J, Marquette K, Ferguson D, Zhong X. D'Antona AM, et al. Among authors: marquette k. Int J Mol Sci. 2024 Feb 5;25(3):1931. doi: 10.3390/ijms25031931. Int J Mol Sci. 2024. PMID: 38339208 Free PMC article.
PF-06804103, A Site-specific Anti-HER2 Antibody-Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers.
Graziani EI, Sung M, Ma D, Narayanan B, Marquette K, Puthenveetil S, Tumey LN, Bikker J, Casavant J, Bennett EM, Charati MB, Golas J, Hosselet C, Rohde CM, Hu G, Guffroy M, Falahatpisheh H, Finkelstein M, Clark T, Barletta F, Tchistiakova L, Lucas J, Rosfjord E, Loganzo F, O'Donnell CJ, Gerber HP, Sapra P. Graziani EI, et al. Among authors: marquette k. Mol Cancer Ther. 2020 Oct;19(10):2068-2078. doi: 10.1158/1535-7163.MCT-20-0237. Epub 2020 Aug 3. Mol Cancer Ther. 2020. PMID: 32747418
Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.
Tumey LN, Leverett CA, Vetelino B, Li F, Rago B, Han X, Loganzo F, Musto S, Bai G, Sukuru SC, Graziani EI, Puthenveetil S, Casavant J, Ratnayake A, Marquette K, Hudson S, Doppalapudi VR, Stock J, Tchistiakova L, Bessire AJ, Clark T, Lucas J, Hosselet C, O'Donnell CJ, Subramanyam C. Tumey LN, et al. Among authors: marquette k. ACS Med Chem Lett. 2016 Jun 22;7(11):977-982. doi: 10.1021/acsmedchemlett.6b00195. eCollection 2016 Nov 10. ACS Med Chem Lett. 2016. PMID: 27882194 Free PMC article.
Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature.
Visintin A, Knowlton K, Tyminski E, Lin CI, Zheng X, Marquette K, Jain S, Tchistiakova L, Li D, O'Donnell CJ, Maderna A, Cao X, Dunn R, Snyder WB, Abraham AK, Leal M, Shetty S, Barry A, Zawel L, Coyle AJ, Dvorak HF, Jaminet SC. Visintin A, et al. Among authors: marquette k. Mol Cancer Ther. 2015 Aug;14(8):1868-76. doi: 10.1158/1535-7163.MCT-15-0188. Epub 2015 Jun 18. Mol Cancer Ther. 2015. PMID: 26089370
Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates.
Tumey LN, Li F, Rago B, Han X, Loganzo F, Musto S, Graziani EI, Puthenveetil S, Casavant J, Marquette K, Clark T, Bikker J, Bennett EM, Barletta F, Piche-Nicholas N, Tam A, O'Donnell CJ, Gerber HP, Tchistiakova L. Tumey LN, et al. Among authors: marquette k. AAPS J. 2017 Jul;19(4):1123-1135. doi: 10.1208/s12248-017-0083-7. Epub 2017 Apr 24. AAPS J. 2017. PMID: 28439809
27 results